Acrux (ASX:ACR) - CEO & Managing Director, Michael Kotsanis
CEO & Managing Director, Michael Kotsanis
Source: Boardroom Media
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Acrux (ACR) was up as much as 54 per cent today after receiving U.S. Food and Drug Administration (FDA) approval for its testosterone topical solution
  • The product will be commercialised by Dash Pharmaceuticals after a sales agreement was entered in October 2020
  • Acrux’s topical solution is used for replacement therapy in males with conditions associated with a deficiency or absence of testosterone
  • Current treatments for low testosterone include medication, weight loss, hormone replacement and medical procedures
  • Acrux is still up a healthy 45.5 per cent and shares are trading at 24 cents

Acrux (ACR) was up as much as 54 per cent today after receiving U.S. Food and Drug Administration (FDA) approval for its testosterone topical solution.

This FDA approval means Acrux can manufacture and market the solution.

On October 12, Acrux entered a sales, marketing and distribution agreement with Dash Pharmaceuticals, which will see Dash become responsible for commercialisation of the product in the U.S.

Both companies will share the profits generated from the sales.

“FDA approval is a major milestone for Acrux and its generics strategy. It is a testament to the hard work and dedication of the product development and regulatory team,” CEO and Managing Director Michael Kotsanis said.

“We are excited to partner with Dash Pharmaceuticals to bring this product to market in the current financial year,” he added.

The testosterone solution is used to treat adult males who have little to no testosterone. Acrux’s topical treatment is used for replacement therapy in males with conditions associated with a deficiency or absence of testosterone such as primary hypogonadism (which is simply decreased testosterone production).

Current treatments for low testosterone include medication, weight loss, hormone replacement and medical procedures.

Acrux is still up a healthy 45.5 per cent and shares are trading at 24 cents at 12:18 pm AEDT.

ACR by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars